TrialHaematologica2013

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Reyes Arranz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.